Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Humana
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$360.65
Massimo di 52 settimane	US$380.86
Minimo di 52 settimane	US$163.11
Beta	0.77
Variazione di 1 mese	16.13%
Variazione a 3 mesi	112.27%
Variazione di 1 anno	48.17%
Variazione a 3 anni	-20.99%
Variazione a 5 anni	-18.17%
Variazione dall'IPO	30,152.45%

Notizie e aggiornamenti recenti

Articolo di analisi • Jun 16

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...

Aggiornamento della narrazione • Jun 08

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.

Recent updates

Articolo di analisi • Jun 16

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Aggiornamento della narrazione • Jun 08

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Aggiornamento della narrazione • May 25

HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing

Humana's updated analyst price target of about $371, up from roughly $322, reflects analysts' focus on stabilizing managed care trends, expectations around Medicare Advantage margin recovery, and a shift to a slightly higher discount rate and profit margin in the underlying assumptions. Analyst Commentary Recent Street research on Humana centers on how quickly Medicare Advantage margins might stabilize, how medical loss ratios track against company targets, and what that could mean for valuation as managed care trends settle.

Seeking Alpha • May 18

Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)

Summary Humana Inc. is upgraded to Buy as shares rebound from a >65% decline, supported by improved CMS rate decisions and activist investor involvement. Despite 2026 EPS guidance below Q1 levels, HUM targets a sustainable 3%+ Medicare Advantage margin and long-term earnings growth by 2028. Recent Q1 results exceeded revenue and adjusted EPS expectations, with a favorable medical benefit ratio and affirmed 25% MA membership growth for 2026. Activist pressure and management’s focus on pricing, benefit adjustments, and operational discipline position HUM for a potential return to >$450/share by 2028. Read the full article on Seeking Alpha

Aggiornamento della narrazione • May 03

HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing

Humana's updated fair value estimate has moved from $302.11 to $322.19 as analysts adjust price targets higher across multiple firms, citing recent research that reflects revised revenue growth, margin expectations, and a higher assumed future P/E of 14.99. Analyst Commentary Recent Street research around Humana has shifted from sharp cuts earlier in the year to a cluster of higher price targets more recently.

Aggiornamento della narrazione • Apr 19

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty

Humana's updated analyst price target edges slightly lower to about $210, as analysts balance recent target cuts tied to Medicare Advantage margin concerns with more recent upward revisions that reflect adjusted models, a modestly lower discount rate, and a slightly different profit margin and forward P/E outlook. Analyst Commentary Recent Street research on Humana reflects a split view, with some analysts revising price targets higher after updating models, while others remain cautious following earlier target cuts and rating downgrades tied to Medicare Advantage margins and CMS rate decisions.

Aggiornamento della narrazione • Apr 04

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility. Analyst Commentary Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power.

Aggiornamento della narrazione • Mar 21

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds

Humana's updated analyst price target has been trimmed by about $12 to $212.17, as analysts factor in more cautious assumptions around Medicare Advantage margins, earnings guidance, and recent sector wide target cuts following Q4 results and regulatory news. Analyst Commentary Recent research on Humana reflects a clear reset in expectations, with price targets moving lower and ratings clustered around neutral.

Aggiornamento della narrazione • Mar 07

HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential

Our updated Humana fair value estimate moves from $287.38 to $223.88, reflecting analysts' lower price targets across the Street as they factor in uncertainty around Medicare Advantage margin improvement, EPS guidance drivers, and the profitability of recent membership growth. Analyst Commentary Recent Street research around Humana has turned more cautious, with multiple firms cutting price targets and some shifting to more neutral stances.

Aggiornamento della narrazione • Feb 21

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.

Aggiornamento della narrazione • Feb 07

HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path

Narrative Update on Humana The analyst price target for Humana has been reduced by about $18.75. Analysts point to recent downgrades, cautious reactions to CMS rate developments, and more conservative margin assumptions, even as they acknowledge potential longer term sector recovery drivers.

Articolo di analisi • Feb 05

Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%

Humana Inc. ( NYSE:HUM ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...

Aggiornamento della narrazione • Jan 24

HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook

Narrative Update Analysts have trimmed their price expectations for Humana, with the updated fair value estimate moving from about US$224 to roughly US$218. This reflects a higher discount rate, more cautious profit margin assumptions, and a lower future P/E multiple, even though modeled revenue growth is higher and recent research views are a mix of supportive and more restrained perspectives.

Aggiornamento della narrazione • Jan 08

HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook

Humana's updated analyst price target has edged down by about $1 to roughly $287. Analysts are balancing slightly higher long term revenue and margin assumptions with mixed ratings that range from Sell to Outperform across recent research.

Articolo di analisi • Dec 19

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...

Aggiornamento della narrazione • Dec 14

HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead

Analysts have modestly increased Humana's fair value estimate by about $2 to roughly $288, reflecting slightly stronger projected revenue growth and improved earnings visibility, even as they incorporate more conservative sector margin assumptions and ongoing concerns about Medicare Advantage and Medicaid cyclicality. Analyst Commentary Recent Street research paints a mixed picture for Humana, with modest upside to fair value supported by improving earnings visibility, but tempered by meaningful concerns around Medicare Advantage dynamics, contract diversification efforts, and broader managed care cyclicality.

Articolo di analisi • Dec 05

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...

Aggiornamento della narrazione • Nov 30

HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts

Humana's analyst price target has been modestly reduced from $288.46 to $286.63. Analysts are factoring in more conservative margin assumptions following recent quarterly results and updated evaluations of the company's revenue growth and profitability outlook.

Articolo di analisi • Nov 16

Humana (NYSE:HUM) Has Announced A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...

Aggiornamento della narrazione • Nov 15

HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover

Humana's analyst price target has been revised lower by approximately $7 to $288.46. Analysts cite a more cautious outlook on margins and an uneven recovery in Medicare Advantage profitability.

Articolo di analisi • Nov 13

Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings

Investors were disappointed with the weak earnings posted by Humana Inc. ( NYSE:HUM ). However, our analysis suggests...

Articolo di analisi • Nov 02

Humana (NYSE:HUM) Will Pay A Dividend Of $0.885

The board of Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend on the 30th of January, with investors...

Aggiornamento della narrazione • Nov 01

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Humana's analyst price target increased slightly, rising by approximately $0.83 to $295.38. Analysts cite mixed dynamics in Medicare Advantage star ratings and improving earnings visibility as factors supporting cautious optimism.

Aggiornamento della narrazione • Oct 18

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s analyst price target increased slightly to $294.54 from $292.87. Analysts cite improved earnings visibility and the stability of Medicare Advantage star ratings as supporting factors for the upward revision.

Aggiornamento della narrazione • Oct 04

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana's analyst price target has fallen from approximately $299 to $293 per share, as analysts cite ongoing challenges in Medicare Advantage star ratings and a more cautious growth outlook. This comes despite recent plan diversification efforts.

Aggiornamento della narrazione • Sep 05

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.

Articolo di analisi • Aug 26

Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) will pay a dividend of $0.885 on the 31st of October. The dividend yield is 1.2% based on this...

Articolo di analisi • Aug 15

Humana Inc. (NYSE:HUM) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

NYSE:HUM 1 Year Share Price vs Fair Value Explore Humana's Fair Values from the Community and select yours Humana Inc...

Seeking Alpha • Feb 12

Humana Q4 Earnings Review: A Tough Quarter -- And A Rating Downgrade

Summary Humana Inc.'s Q4 and full-year 2024 earnings report shows a 10% revenue increase but significant losses, highlighting major structural issues in its business model. Rising healthcare utilization and insufficient CMS rate increases have severely impacted Humana's profitability, with shares down 50% from their 2023 peak. New management aims to improve efficiency and service quality, but the company's future hinges on CMS rate decisions and star-rating litigation outcomes. Given the high uncertainty and potential for further losses, I recommend a “Hold” on HUM shares unless willing to take substantial risk. Read the full article on Seeking Alpha

Seeking Alpha • Jan 10

Humana's Growth Vs. Rising Costs: Why It's A Hold For Cautious Investors

Summary Humana is doubling down on Medicare Advantage and healthcare services while cutting less profitable areas. Higher costs and lower profit margins are putting pressure on the business right now. Medicare Advantage growth and expanding healthcare services show long-term potential. Regulatory changes and restructuring costs could make the next couple of years bumpy. The stock looks fairly priced, so holding for now seems like the best move. Read the full article on Seeking Alpha

Seeking Alpha • Dec 18

Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?

Summary The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability. Given the current low valuations, I reaffirm both Humana and Cigna as 'buy' candidates, as potential regulatory impacts may already be priced in. Read the full article on Seeking Alpha

Seeking Alpha • Dec 05

Humana: Medicare Advantage Is Just A Short-Term Problem

Summary Humana's stock has declined 18% while the S&P 500 returned 13.5%, driven by short-term issues with Medicare Advantage. Despite short-term cost challenges, Medicare Advantage remains a long-term tailwind, and CenterWell coordinated care isn't priced into Humana's strategy. I maintain buy rating at a price target of $370, 28% upside. Read the full article on Seeking Alpha

Rendimenti per gli azionisti

	HUM	US Healthcare	US Mercato
7D	-2.2%	-1.2%	2.0%
1Y	48.2%	16.8%	23.3%

Ritorno vs Industria: HUM ha superato il US Healthcare che ha restituito 16.8 % nell'ultimo anno.

Rendimento vs Mercato: HUM ha superato il mercato US che ha restituito 23.3 % nell'ultimo anno.

Volatilità dei prezzi

Is HUM's price volatile compared to industry and market?
HUM volatility
HUM Average Weekly Movement	6.4%
Healthcare Industry Average Movement	7.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: HUM non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di HUM è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1961	67,060	Jim Rechtin	www.humana.com

Humana Inc. fornisce prodotti assicurativi medici e speciali negli Stati Uniti. Opera in due segmenti, Insurance e CenterWell. Il segmento Assicurazioni offre prodotti Medicare Advantage individuali, che comprendono prestazioni di assicurazione sanitaria, tra cui programmi di benessere, gestione delle cure croniche e coordinamento delle cure; prodotti Medicare individuali autonomi con prescrizione di farmaci (PDP); Medicare Advantage di gruppo e Medicare PDP autonomi; supplementi Medicare; assicurazioni speciali e accessorie che comprendono odontoiatria, vista, vita e invalidità; servizi amministrativi per l'organizzazione di servizi di assistenza sanitaria per il personale militare in servizio attivo e in pensione e per le persone a carico, nonché per i gestori di prestazioni farmaceutiche.

Humana Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Humana con la sua capitalizzazione di mercato?
HUM statistiche fondamentali
Capitalizzazione di mercato	US$43.46b
Utili (TTM)	US$1.13b
Ricavi(TTM)	US$137.20b

38.3x

Rapporto P/E

0.3x

Rapporto P/S

HUM è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HUM Conto economico (TTM)
Ricavi	US$137.20b
Costo del fatturato	US$117.98b
Profitto lordo	US$19.22b
Altre spese	US$18.09b
Utili	US$1.13b

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

Jul 29, 2026

Utile per azione (EPS)	9.41
Margine lordo	14.01%
Margine di profitto netto	0.82%
Rapporto debito/patrimonio netto	77.1%

Come si è comportato HUM nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.0%

Rendimento attuale del dividendo

38%

Rapporto di remunerazione

HUM paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di HUM

Quando è necessario acquistare HUM per ricevere un dividendo imminente?
Humana date dei dividendi
Data di stacco del dividendo	Jun 26 2026
Data di pagamento dei dividendi	Jul 31 2026
Giorni fino al dividendo Ex	7 days
Giorni prima della data di pagamento dei dividendi	42 days

HUM paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di HUM

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/06/18 21:49
Prezzo dell'azione a fine giornata	2026/06/18 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Humana Inc. è coperta da 37 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
David Toung	Argus Research Company
Hua Ha	Baird
Andrew Mok	Barclays

Humana (HUM) Panoramica del titolo

Premi

Analisi del rischio

Analyst Price Targets

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Aging Population And Tech Will Shape Long-Term Medicare Care

Reforms And Rising Costs Will Erode Medicare Margins

Top Community Narratives

Humana Faces Rising Medicare Scrutiny as Compliance Rules Tighten

Top Community Narratives

Humana Faces Rising Medicare Scrutiny as Compliance Rules Tighten

Top Analyst Narratives

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Aging Population And Tech Will Shape Long-Term Medicare Care

Reforms And Rising Costs Will Erode Medicare Margins

Concorrenti di Humana Inc.

Elevance Health

Molina Healthcare

HealthEquity

UnitedHealth Group

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Humana Stock Gains Statewide Illinois Medicaid Contract Expanding Reach to 102 Counties

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana Draws Investor Interest on Growth Outlook Despite Stock Decline and Margin Challenges

Price target increased by 8.8% to US$297

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Price target increased by 9.2% to US$269

Recent updates

Humana Stock Gains Statewide Illinois Medicaid Contract Expanding Reach to 102 Counties

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana Draws Investor Interest on Growth Outlook Despite Stock Decline and Margin Challenges

Price target increased by 8.8% to US$297

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Price target increased by 9.2% to US$269

HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing

Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)

Investor sentiment improves as stock rises 16%

HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing

Price target increased by 12% to US$236

First quarter 2026 earnings: EPS misses analyst expectations

Humana Inc. Revises Earnings Guidance for the Year Ending December 31, 2026

Dividend of US$0.89 announced

CenterWell Introduces the Fulfillment Index

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty

Humana Inc. Declares Quarterly Cash Dividend, Payable on July 31, 2026

Humana Inc. Elects Robert S. Field to the Board of Directors, Effective April 10, 2026

President of CenterWell exercised options and sold US$70k worth of stock

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana Inc. to Report Q1, 2026 Results on Apr 29, 2026

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds

Upcoming dividend of US$0.89 per share

Humana Inc., Annual General Meeting, Apr 16, 2026

HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential

Humana Inc. Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members

Fourth quarter dividend of US$0.89 announced

New minor risk - Earnings quality

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana Inc. Declares Quarterly Cash Dividend, Payable on April 24, 2026

Price target decreased by 12% to US$249

Humana Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026

HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path

Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%

Humana Inc. (NYSE:HUM) completed the acquisition of Familiehjelpgruppen As.

Investor sentiment deteriorates as stock falls 22%

HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook

Humana Inc. to Report Q4, 2025 Results on Feb 11, 2026

HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook

President exercised options and sold US$911k worth of stock

President exercised options and sold US$911k worth of stock

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Upcoming dividend of US$0.89 per share

Humana Inc. Announces Executive Changes

HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts

Humana (NYSE:HUM) Has Announced A Dividend Of $0.885

HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover

Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind